All In MedTech

Device Trial Radar · NCT00121485

Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy

The HeartMate II LVAS Pivotal Study Protocol, Destination Therapy

Last checked: Nov 20, 2026Latest source record: Jun 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingTitle says "pivotal". Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Feb 2005

Primary completion

Jun 2009

Study completion Jan 2012

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
Collaborators
Thoratec Corporation
First posted
Jul 21, 2005

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and effectiveness of the Thoratec HeartMate II Left Ventricular Assist System (LVAS) as Destination Therapy in end-stage heart failure patients who do not qualify for cardiac transplantation. The Destination Therapy indication for use was approved by FDA on January 20, 2010 (ref. PMA P060040/S005).

Conditions

  • Heart Failure, Congestive
  • Ventricular Dysfunction
  • Cardiomyopathies

Interventions

  • Left Ventricular Assist System (LVAS)Device

    Implantation of left ventricular assist device for hemodynamic support

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite EndpointTime frame: Patients' status at 2 years post-implant

Locations

47 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • Sharp Memorial Hospital

    San Diego, California

44 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.